학술논문

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Document Type
Article
Source
Investigational New Drugs; Aug2014, Vol. 32 Issue 4, p700-709, 10p
Subject
VASCULAR endothelial growth factor antagonists
BEVACIZUMAB
OXALIPLATIN
THERAPEUTIC use of antimetabolites
TUMOR markers
ACADEMIC medical centers
ANTINEOPLASTIC agents
BLOOD testing
COMBINATION drug therapy
CLINICAL trials
CONFIDENCE intervals
DIAGNOSTIC imaging
DOSE-response relationship in biochemistry
DRUG dosage
DRUG toxicity
MEDICAL cooperation
HEALTH outcome assessment
POLYMERASE chain reaction
REGRESSION analysis
RESEARCH
RESEARCH funding
STATISTICS
TUMORS
DATA analysis
TREATMENT effectiveness
PROPORTIONAL hazards models
DESCRIPTIVE statistics
KAPLAN-Meier estimator
PHARMACODYNAMICS
THERAPEUTICS
Language
ISSN
01676997
Abstract
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)